Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: A therapeutic dilemma

Annals of Hematology

Volumn 90, Issue 5, 2011, Pages 539-546

  Kim, Seok Jin ^a   Oh, Sung Yong ^b   Kim, Jin Seok ^c   Kim, Hawk ^d   Lee, Gyeong Won ^e   Won, Jong Ho ^f   Shin, Ho Jin ^g   Yang, Deok Hwan ^h   Choi, Chul Won ⁱ   Park, Jinny ^j   Kim, Won Seog ^a   Suh, Cheolwon ^k  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Dong A University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Gyeongsang National University School of Medicine   (South Korea)

^f Soonchunhyang University College of Medicine   (South Korea)

^g Pusan National University School of Medicine   (South Korea)

^h Chonnam National University Research Institute of Medical Sciences   (South Korea)

ⁱ Korea University Ansan Hospital   (South Korea)

^j Gachon University   (South Korea)

^k University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

Central nervous system; Diffuse large B cell lymphoma; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; KOREA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 79956149229     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-010-1104-0     Document Type: Article

References (20)

1. Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, Briere J, Reyes F (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 11:685-690
2. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H (2002) Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 13:1099-1107
3. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105:496-502 (Pubitemid 40070727)
4. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F (1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:1178-1184 (Pubitemid 28086870)
5. MacKintosh FR, Colby TV, Podolsky WJ, Burke JS, Hoppe RT, Rosenfelt FP, Rosenberg SA, Kaplan HS (1982) Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 49:586-595 (Pubitemid 12213461)
6. Bierman P, Giglio P (2005) Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 19:597-609, v
7. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y (2006) Secondary central nervous system lymphoma. Int J Hematol 84:128-135 (Pubitemid 44343975)
8. Dietrich PY, Dietrich PY (2009) Intrathecal MTX for DLBCL: from an inappropriate prophylactic tradition to a medical error? Blood 114:1999, author reply 1999
9. Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M (2009) Response: intrathecal methotrexate and central nervous system events. Blood 114:1999-2000
10. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113:3896-3902
11. Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E (2008) Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 111:1085-1093 (Pubitemid 351213386)
12. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
13. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346 (Pubitemid 26342716)
14. van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E (2008) Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma 49(Suppl 1):52-58
15. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516-the Southwest Oncology Group. J Clin Oncol 27:114-119
16. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289 (Pubitemid 37494085)
17. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ (2009) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 21:1046-1052
18. Shimazu Y, Notohara K, Ueda Y (2009) Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 89:577-583
19. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 15:129-133 (Pubitemid 38139614)
20. Uhm JE, Kim KH, Yi SY, Chang MH, Park KW, Kong DS, Lee JI, do Nam H, Park W, do Lim H, Kim SJ, Kim K, Ko YH, Kim WS (2009) A retrospective study to compare two methotrexatebased regimens for primary central nervous system lymphoma. Leuk Lymphoma 50:1110-1118